Kartos Therapeutics
Phase 1Kartos Therapeutics is a clinical stage biopharmaceutical company with an investigational MDM2 inhibitor, navtemadlin (KRT-232), KRT-232
Founded
2015
Focus
Small Molecules
About
Kartos Therapeutics is a clinical stage biopharmaceutical company with an investigational MDM2 inhibitor, navtemadlin (KRT-232), KRT-232
Funding History
3Total raised: $227M
Series C$105MCormorant Asset ManagementMar 15, 2022
Series B$80MNovo HoldingsJul 15, 2020
Series A$42MArix BioscienceMay 15, 2018
Company Info
TypePrivate
Founded2015
LocationRedwood City, United States
StagePhase 1
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile